SCHEMBL700736

SCHEMBL700736

CCCCC(=O)NCCC

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CASP2 P42575 1/20 0.61
CNR1 P21554 3/20 0.61
FAAH O00519 5/20 0.61
NAAA Q02083 1/20 0.57
DNM1 Q05193 2/20 0.57
EPHX1 P07099 1/20 0.52
MCL1 Q07820 1/20 0.50
EPHX2 P34913 2/20 0.49
SELP P16109 1/20 0.49
TRPM8 Q7Z2W7 1/20 0.49
MEN1 O00255 1/20 0.49
KCNK3 O14649 1/20 0.49
ALDH1A1 P00352 1/20 0.49
CNR2 P34972 1/20 0.49
BLM P54132 1/20 0.49
KMT2A Q03164 1/20 0.49
TRPV1 Q8NER1 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8971354 0.98 CNR1 (0.59) CASP2CNR1FAAHNAAADNM1
SCHEMBL3349108 0.93 FAAH (0.70) CASP2CNR1FAAHNAAADNM1
SCHEMBL14576902 0.92 CASP2 (0.64) CASP2CNR1FAAHNAAADNM1
SCHEMBL16302656 0.92 FAAH (0.63) CASP2CNR1FAAHNAAADNM1
SCHEMBL22992630 0.91 CASP2 (0.63) CASP2CNR1FAAHNAAADNM1
Hexadecanoic Acid Propylamide SCHEMBL1457463 0.91 FAAH (0.74) CASP2CNR1FAAHNAAADNM1
SCHEMBL9964260 0.91 FAAH (0.74) CASP2CNR1FAAHNAAADNM1
SCHEMBL5173746 0.91 FAAH (0.74) CASP2CNR1FAAHNAAADNM1
SCHEMBL8695820 0.91 FAAH (0.74) CASP2CNR1FAAHNAAADNM1
SCHEMBL7760880 0.91 FAAH (0.74) CASP2CNR1FAAHNAAADNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120020119-A Process for preparing N- (2-substituted ethyl) amides and N-vinyl amides 中国石油化工股份有限公司 2025-05-20 CN claimed
US-8143408-B2 N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain ASTRAZENECA AB (SE) 2012-03-27 US claimed
US-20100137322-A1 NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2010-06-03 US claimed
EP-2158198-A2 NOVEL N- (8HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN AstraZeneca AB (SE) 2010-03-03 EP claimed
WO-2008130320-A2 NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2008-10-30 WO claimed
US-12630731-B2 Non-aqueous ink composition DNP FINE CHEMICALS CO., LTD. (JP) 2026-05-19 US disclosed
US-20260125570-A1 NONAQUEOUS INK COMPOSITION, RECORDING METHOD, METHOD FOR PRODUCING RECORDED MATERIAL, INK SET, RECORDED MATERIAL, AND INKJET RECORDING APPARATUS DNP FINE CHEMICALS CO., LTD. (JP) 2026-05-07 US disclosed
US-12590216-B2 Water-based ink and ink set including same DNP FINE CHEMICALS CO., LTD. (JP) 2026-03-31 US disclosed
US-12522744-B2 Ink set DNP FINE CHEMICALS CO., LTD. (JP) 2026-01-13 US disclosed
US-20250368766-A1 RESIN, RESIN DISPERSION, AND RESIN COMPOSITION DNP FINE CHEMICALS CO., LTD. (JP) 2025-12-04 US disclosed
EP-4617333-A1 NONAQUEOUS INK COMPOSITION, RECORDING METHOD, METHOD FOR PRODUCING RECORDED MATERIAL, INK SET, RECORDED MATERIAL, AND INKJET RECORDING APPARATUS DNP Fine Chemicals Co., Ltd. (JP) 2025-09-17 EP disclosed
US-12398444-B2 Diglycolamide derivatives for separation and recovery of rare earth elements from aqueous solutions UT-BATTELLE, LLC (US) 2025-08-26 US disclosed
US-4855292-A ANTIMICROBIAL AGENTS OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1989-08-08 US disclosed
EP-0308325-A1 Process for the preparation of di-N-propyl acetonitrile SANOFI (FR) 1989-03-22 EP disclosed
CN-1030237-A BENZOHETEROCYCLIC COMPOUNDS OTSUKA PHARMA CO LTD (JP) 1989-01-11 CN disclosed
EP-0287951-A2 7-Piperazinyl- or 7-Morpholino-4-oxo-quinoline-3-carboxylic acid derivatives, their preparation and their use as antimicrobial agents OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1988-10-26 EP disclosed
EP-0267024-A2 Hydrofluorene derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1988-05-11 EP disclosed
EP-0091519-B1 TOPICAL ACYLAMINOPHENOLS Johnson & Johnson Products Inc. (US) 1987-06-24 EP disclosed
EP-0091519-A1 Topical acylaminophenols Johnson & Johnson Products Inc. (US) 1983-10-19 EP disclosed
US-4329366-A ANTIINFLAMMATORY AGENTS JOHNSON & JOHNSON PRODUCTS, INC. (US) 1982-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137322-A1 NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN OPRL1, OPRK1, OPRD1 CASP2 1644/4885CNR1 8/4885FAAH 23/4885
US-12630731-B2 Non-aqueous ink composition EXOSC10, RPP30, RPS20 CASP2 4166/4885CNR1 4829/4885FAAH 4881/4885
US-12590216-B2 Water-based ink and ink set including same TYR, ITGB3, ARCN1 CASP2 3784/4885CNR1 4868/4885FAAH 4817/4885
US-12398444-B2 Diglycolamide derivatives for separation and recovery of rare earth elements from aqueous solutions GNE, GALE, ARGLU1 CASP2 4128/4885CNR1 3317/4885FAAH 4539/4885
US-20260125570-A1 NONAQUEOUS INK COMPOSITION, RECORDING METHOD, METHOD FOR PRODUCING RECORDED MATERIAL, INK SET, RECORDED MATERIAL, AND INKJET RECORDING APPARATUS BMI1, IK, PRDM9 CASP2 4563/4885CNR1 4860/4885FAAH 4829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.